Who are 177Lu-edotreotide's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Copper Cu 64 Dotatate, Signifor (pasireotide), Somatostatin analog, 68Ga-DOTATOC, IPN10200, 177Lu-DOTA0-Tyr3-Octreotate.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/177lu-edotreotide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

177Lu-edotreotide — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

177Lu-edotreotide (177Lu-edotreotide) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Radioligand therapeutic; somatostatin receptor agonist. Area: Oncology.

phase 3 Radioligand therapeutic; somatostatin receptor agonist Somatostatin receptor 2 (SSTR2) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

177Lu-edotreotide (177Lu-edotreotide) — Grupo Espanol de Tumores Neuroendocrinos. 177Lu-edotreotide is a radioligand therapeutic that binds to somatostatin receptor 2 (SSTR2) on neuroendocrine tumor cells and delivers targeted radiation to kill them.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
177Lu-edotreotide TARGET	177Lu-edotreotide	Grupo Espanol de Tumores Neuroendocrinos	phase 3	Radioligand therapeutic; somatostatin receptor agonist	Somatostatin receptor 2 (SSTR2)
Copper Cu 64 Dotatate	Copper Cu 64 Dotatate	Vanderbilt-Ingram Cancer Center	marketed	Radiopharmaceutical; somatostatin receptor agonist imaging agent	Somatostatin receptor 2 (SSTR2)
Signifor (pasireotide)	Signifor (pasireotide)	Zealand University Hospital	marketed	Somatostatin receptor agonist	Somatostatin receptors (SSTR1, SSTR3, SSTR5)
Somatostatin analog	Somatostatin analog	The Netherlands Cancer Institute	marketed	Somatostatin receptor agonist	Somatostatin receptors (SSTR2, SSTR5)
68Ga-DOTATOC	68Ga-DOTATOC	Montefiore Medical Center	phase 3	Radiolabeled somatostatin receptor agonist; PET imaging agent	Somatostatin receptor 2 (SSTR2); somatostatin receptors
IPN10200	IPN10200	Ipsen	phase 3	Somatostatin receptor agonist	Somatostatin receptors (SSTR)
177Lu-DOTA0-Tyr3-Octreotate	177Lu-DOTA0-Tyr3-Octreotate	Advanced Accelerator Applications	phase 3	Radiolabeled peptide; somatostatin receptor agonist	Somatostatin receptor 2 (SSTR2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Radioligand therapeutic; somatostatin receptor agonist class)

Grupo Espanol de Tumores Neuroendocrinos · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). 177Lu-edotreotide — Competitive Intelligence Brief. https://druglandscape.com/ci/177lu-edotreotide. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab